ralfinamide ralfinamide ralfinamide (inn) (code names nw-1029, fce-26742a, pnu-0154339e) is a multimodal drug which is under investigation by newron pharmaceuticals for the treatment of neuropathic pain and other pain conditions such as post-operative dental pain. not to be confused with rufinamide. ralfinamideclinical dataatc codenoneidentifiers iupac name n2--l-alaninamide cas number133865-88-0pubchem cid5745207chemspider4676525unii3lpf0s0gvvchemblchembl2107771comptox dashboard (epa)dtxsid70158406 echa infocard100.120.272 chemical and physical dataformulac17h19fn2o2molar mass302.349 g·mol−13d model (jsmol)interactive image smiles c(c(=o)n)ncc1ccc(cc1)occ2ccccc2f inchi inchi=1s/c17h19fn2o2/c1-12(17(19)21)20-10-13-6-8-15(9-7-13)22-11-14-4-2-3-5-16(14)18/h2-9,12,20h,10-11h2,1h3,(h2,19,21)/t12-/m0/s1key:bhjibofhefdsau-lbprgkrzsa-n it has a relatively complex pharmacology, acting as a mixed voltage-gated sodium channel blocker (including nav1.7), n-type calcium channel blocker, noncompetitive nmda receptor antagonist, and monoamine oxidase b inhibitor. it has thus far progressed as far as phase iib/phase iii clinical trials. in 2010 it failed a phase ii trial for lower back pain. encouraging phase ii results have been announced for neuropathic pain.